Arovella Therapeutics Limited (AU:ALA)
ASX:ALA
Want to see AU:ALA full AI Analyst Report?
Top Page
Arovella Therapeutics Limited
(Sydney:ALA)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.07
▼(-7.50% Downside)
Action:ReiteratedDate:05/05/26
The score is primarily constrained by heavy ongoing losses and consistent cash burn, despite a low-debt balance sheet. Technically, the stock remains in a broader downtrend (below key moving averages), with only modest signs of near-oversold stabilization. Valuation support is limited because the company is unprofitable and offers no dividend.
Positive Factors
Very low leverage / no debt
Zero reported debt meaningfully reduces financial risk and interest burden for an early‑stage biotech. This structural advantage gives management flexibility to allocate equity capital to R&D and partnerships, extending strategic optionality and lowering near‑term refinancing pressure over the next several months.
Negative Factors
Consistent negative cash generation
Persistent negative operating and free cash flow means the company is not self‑funding and must rely on external capital or partnerships. Over 2‑6 months this elevates dilution and financing risk, constraining the pace of parallel clinical programs and strategic flexibility absent new funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / no debt
Zero reported debt meaningfully reduces financial risk and interest burden for an early‑stage biotech. This structural advantage gives management flexibility to allocate equity capital to R&D and partnerships, extending strategic optionality and lowering near‑term refinancing pressure over the next several months.
Read all positive factors
Arovella Therapeutics Limited (ALA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$91.87M
Dividend YieldN/A
Average Volume (3M)1.58M
Price to Earnings (P/E)―
Beta (1Y)1.71
Revenue Growth-100.00%
EPS Growth-11.11%
CountryAU
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,208,783,700
10 Day Avg. Volume1,549,358
30 Day Avg. Volume1,578,675
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)5.47
Price to Sales (P/S)806.87
P/FCF Ratio-14.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Arovella Therapeutics Limited Business Overview & Revenue Model
Company Description
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes Zolpi...
How the Company Makes Money
null...
Arovella Therapeutics Limited Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -3.30M | 136.00K | 17.00K | 405.90K | 295.81K | 257.35K |
| Gross Profit | -3.36M | 136.00K | -25.98K | -3.00M | 88.75K | 34.60K |
| EBITDA | -14.93M | -11.10M | -10.63M | -10.37M | -7.87M | -4.99M |
| Net Income | -7.93M | -7.51M | -8.75M | -10.18M | -8.62M | -5.05M |
Balance Sheet | ||||||
| Total Assets | 20.25M | 21.60M | 13.28M | 5.47M | 9.21M | 10.69M |
| Cash, Cash Equivalents and Short-Term Investments | 19.37M | 20.88M | 12.71M | 5.18M | 6.07M | 6.72M |
| Total Debt | 0.00 | 0.00 | 0.00 | 144.80K | 144.80K | 79.23K |
| Total Liabilities | 1.33M | 1.52M | 2.06M | 1.69M | 1.60M | 1.71M |
| Stockholders Equity | 18.92M | 20.08M | 11.23M | 3.78M | 7.62M | 8.98M |
Cash Flow | ||||||
| Free Cash Flow | -6.93M | -7.34M | -7.04M | -6.40M | -6.83M | -4.06M |
| Operating Cash Flow | -6.82M | -6.93M | -6.91M | -6.40M | -6.27M | -3.54M |
| Investing Cash Flow | -122.36K | -432.11K | -179.34K | 95.42K | -566.00K | -514.55K |
| Financing Cash Flow | 14.59M | 15.52M | 14.61M | 5.41M | 6.19M | 9.80M |
Arovella Therapeutics Limited Technical Analysis
Neutral
0.08
Price Trends
0.08
Positive
0.08
Negative
0.09
Negative
Market Momentum
<0.01
Negative
53.39
Neutral
62.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALA, the sentiment is Neutral. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.08, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.39 is Neutral, neither overbought nor oversold. The STOCH value of 62.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ALA.
Arovella Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$29.40M | -25.86 | 10.35% | 2.81% | -18.17% | -70.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$66.70M | -3.83 | -24.81% | ― | ― | 26.64% | |
44 Neutral | AU$91.87M | -14.80 | -40.65% | ― | -100.00% | -11.11% | |
41 Neutral | AU$119.63M | -2.12 | -30.19% | ― | ― | 62.50% | |
41 Neutral | AU$28.91M | -4.45 | -93.66% | ― | -23.71% | -16.02% | |
41 Neutral | AU$144.59M | -2.84 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:ALA
Arovella Therapeutics Limited
0.08
>-0.01
-9.52%
AU:ATX
Amplia Therapeutics
0.13
0.08
136.36%
AU:ATH
Alterity Therapeutics
0.01
>-0.01
-8.33%
AU:PIQ
Proteomics International Laboratories Ltd.
0.18
-0.19
-51.39%
AU:EZZ
EZZ Life Science Holdings Ltd.
0.63
-0.79
-55.95%
AU:RCE
Recce Pharmaceuticals Ltd.
0.50
0.20
66.67%
Arovella Therapeutics Limited Corporate Events
Arovella Therapeutics Options Lapse Clarifies Capital Structure
May 8, 2026
Arovella Therapeutics has reported the cessation of 5,668,280 options, identified under the ASX security code ALAAA, after these conditional rights lapsed because their conditions were not met or could no longer be satisfied. The options, which we...
Arovella Therapeutics Reports Director Andrew Nash’s Departure With No Security Interests
May 7, 2026
Arovella Therapeutics Limited has notified the ASX that Andrew Nash ceased to be a director of the company effective 4 May 2026. The final director’s interest notice confirms that Nash held no relevant interests in Arovella securities or rel...
Arovella Highlights Solid-Tumour CAR-iNKT Advances at Global Cell Therapy Meeting
May 7, 2026
Arovella Therapeutics showcased new pre-clinical data on its CLDN18.2-directed CAR-iNKT cell therapy for gastric and pancreatic cancers at the ISCT 2026 cell and gene therapy conference in Dublin. The poster, led by company scientist Dr Clinton He...
Arovella names acting CEO as it heads into key Phase I trial
May 7, 2026
Arovella Therapeutics has appointed Chief Operating Officer Dr Nicole Van Der Weerden as acting chief executive officer following the resignation and termination of former CEO Dr Michael Baker. Her remuneration has been lifted to match her predece...
Arovella Overhauls Board as CEO Resigns, Launches Strategic Review
May 4, 2026
Arovella Therapeutics has undergone a major board overhaul after receiving a shareholder requisition to remove two directors, prompting the resignation of Chief Executive Officer and Managing Director Dr Michael Baker, who will serve a three-month...
Arovella Appoints New Director With No Current Shareholdings
May 1, 2026
Arovella Therapeutics Limited has announced the appointment of David John Williams as a director effective 28 April 2026. According to the initial director’s interest notice filed with the ASX, Williams currently holds no relevant interests ...
Arovella boosts board with four senior biotech and finance appointments
Apr 28, 2026
Arovella Therapeutics has strengthened its board as part of a broader succession strategy, appointing seasoned Pharma and Biotech executive Dr Mike Perry as a Non-Executive Director. Dr Perry brings more than 30 years of global experience across b...
Arovella shareholder withdraws invalid requisition, easing governance overhang
Apr 22, 2026
Arovella Therapeutics has announced that the shareholder who previously issued an invalid requisition notice under section 249D of the Corporations Act has now withdrawn that notice. The withdrawal removes a potential source of corporate distracti...
Arovella Rejects Shareholder Board Requisition as Invalid
Apr 22, 2026
Arovella Therapeutics has rejected a shareholder’s attempt to overhaul its board, declaring a purported notice under section 249D of the Corporations Act invalid and confirming it will not convene a general meeting in response. The company s...
Arovella Showcases CLDN18.2 CAR-iNKT Solid Tumour Data at AACR
Apr 20, 2026
Arovella Therapeutics presented new pre-clinical data on its CLDN18.2-targeting CAR-iNKT cell therapy at the American Association for Cancer Research annual meeting in San Diego. The poster detailed how CLDN18.2 CAR-iNKT cells effectively killed C...
Arovella Boosts Cash Reserves with Additional R&D Tax Rebate
Apr 14, 2026
Arovella Therapeutics has received an additional A$0.28 million under Australia’s RD Tax Incentive, linked to eligible overseas research expenditure for FY2025 that was recognised after its original tax return, which had already generated a ...
Arovella Options Lapse, Simplifying Capital Structure
Apr 12, 2026
Arovella Therapeutics Limited has announced the cessation of 4,000,000 listed options (ASX code ALAAE) that expired on 10 April 2026 without being exercised. The lapse of these options reduces the pool of potential future shares, slightly simplify...
Arovella Therapeutics Seeks ASX Quotation for 1.6 Million New Shares
Apr 10, 2026
Arovella Therapeutics has applied to the ASX for quotation of 1,600,000 new ordinary fully paid shares, with an issue date of 8 April 2026. The additional securities arise from the exercise or conversion of existing options or other convertible in...
Arovella issues 1.6m new shares and affirms regulatory compliance
Apr 10, 2026
Arovella Therapeutics has issued 1,600,000 new ordinary shares on 8 April 2026 and notified the market that this issuance was conducted without a disclosure document under the Corporations Act. The company confirmed it is up to date with its finan...
Arovella Weighs Validity of Requisitioned Meeting for Board Appointments
Apr 10, 2026
Arovella Therapeutics has received a purported shareholder notice under section 249D of the Corporations Act from The Trust Company (Australia) Limited SBF A/C, which holds more than 5% of its voting shares. The notice requests a general meeting w...
Arovella’s Armoured CLDN18.2 CAR-iNKT Cells Show Strong Activity Against Gastric and Pancreatic Cancer In Vitro
Apr 1, 2026
Arovella Therapeutics has demonstrated that its novel CLDN18.2-targeting CAR engineered into iNKT cells can effectively kill CLDN18.2-positive pancreatic and gastric cancer cells in vitro. The studies, conducted at the University of North Carolina...
Arovella Wins TGA Green Light to Run ALA-101 Cell Therapy Trial Under Streamlined CTN Pathway
Mar 15, 2026
Arovella Therapeutics has received confirmation from Australia’s Therapeutic Goods Administration that its planned Phase 1 trial of ALA-101, an allogeneic CD19-targeting CAR-iNKT cell therapy, can proceed under the Clinical Trial Notificatio...
Arovella Therapeutics Announces Departure of Director Gary Phillips
Feb 9, 2026
Arovella Therapeutics Limited has disclosed that director Gary Phillips ceased to be a director of the company on 9 February 2026. The filing notes that at the time of his departure, Phillips held indirect interests comprising 788,888 fully paid o...
Arovella reshapes board as CAR-iNKT cell therapy program advances
Feb 9, 2026
Arovella Therapeutics has announced the retirement of Interim Chair and Non-Executive Director Dr Elizabeth Stoner and Non-Executive Director Gary Phillips, both effective 9 February 2026. In response to these significant board changes, the compan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.